杰特贝林遗传性血管性水肿治疗药物在华上市申请获受理

Core Viewpoint - Jetabelin's innovative drug FXIIa inhibitor monoclonal antibody (garadacimab) has received acceptance for market application in China for the prevention of hereditary angioedema (HAE) attacks [1] Group 1: Product Information - Garadacimab is the world's first and currently the only drug targeting factor XIIa (FXIIa) for preventive treatment of HAE [1] - HAE is a rare, potentially life-threatening genetic disease characterized by recurrent and unpredictable swelling of the skin and/or submucosa [1] Group 2: Regulatory Approval - The drug has already obtained marketing authorization in several countries and regions, including the United States, European Union, United Kingdom, Japan, Australia, Switzerland, and the United Arab Emirates [1]